Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

02002 A SAFETY STUDY OF DEXTRIN SULPHATE VAGINAL MICROBICIDE

Bukenya Michael*
Julie Pickering*, Stella Mukwaya*,Romano Byaruhanga**, Charles Lacey***, Jimmy Whitworth*, and Pius Okong**
*Medical Research Councl Programme on AIDS in Uganda, **St Francis Hospital Nsamby, Uganda, ***Imperial College, London.

Background
We perfomed a randomised placebo controlled trial to assess safety of 4% intravaginal dextrin sulphate gelat a hospital in Kampala, Uganda.

Methods
Sexually active females of reproductive age were screened for eligibility of the study. Those found to have sexually transmitted infections were treated before entry. Consentig females were allocated toactive gel or its matched vehicle placebo, pre sex active gel and observation only arm. Total follow up lasted 8 weeks during which women were interviewed, examined by colposcopy and labaratory tests(HIV test, STD screening, haematology, coagulation and clinical chemistry ) perfomed.

Results
A total of 109 females were enrolled(71 HIV negative & 38HIV positive); 80 to use gel twice a day[65active gel, 15 placebo], 9 active gel pre sex and 20 observation only arm. In 7/322(2.2%) colposcopy exams, abnormalities were documented among females using active gel, and in 11/74(14.9%)within the placebo group. Only 2 of the 18 abnormalities were thought to be gel related. 6/65(9%) participants on active gel twice daily reported mild intermenstrual spotting, compared to 2/15(13%) using placebo, and 3/20(15%) using no gel. 8/65(12%) participants on active gel reported excessive thirst during the first week of gel use. No excess genital irritation, no evidence of change in vaginal flora, no evidence of systemic toxicity were observed as a result of gel use.

Conclusion
The results indicate a satisfactory safety profile of dextrin sulphate 4% gel in sexually active African population. In particular colposcopic abnormalities did not appear more frequent in the active gel arm. Temporary occurrence of excessive thirst may require further research.

Michael Bukenya
medical research council p.o. box 49 Entebbe
(Telephone) 031 262910 (E-mail) michael.bukenya@mrcuganda.org